• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用CpG-A和CpG-B寡核苷酸激活可揭示人类浆细胞样树突状细胞中I型干扰素合成的两种不同调节途径。

Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells.

作者信息

Kerkmann Miren, Rothenfusser Simon, Hornung Veit, Towarowski Andreas, Wagner Moritz, Sarris Anja, Giese Thomas, Endres Stefan, Hartmann Gunther

机构信息

Department of Internal Medicine, Division of Clinical Pharmacology, University of Munich, Munich, Germany.

出版信息

J Immunol. 2003 May 1;170(9):4465-74. doi: 10.4049/jimmunol.170.9.4465.

DOI:10.4049/jimmunol.170.9.4465
PMID:12707322
Abstract

Two different CpG oligonucleotides (ODN) were used to study the regulation of type I IFN in human plasmacytoid dendritic cells (PDC): ODN 2216, a CpG-A ODN, known to induce high amounts of IFN-alpha in PDC, and ODN 2006, a CpG-B ODN, which is potent at stimulating B cells. CpG-A ODN showed higher and prolonged kinetics of type I IFN production compared with that of CpG-B ODN. In contrast, CpG-B ODN was more active than CpG-A ODN in stimulating IL-8 production and increasing costimulatory and Ag-presenting molecules, suggesting that CpG-A and CpG-B trigger distinct regulatory pathways in PDC. Indeed, CpG-A ODN, but not CpG-B ODN, activated the type I IFNR-mediated autocrine feedback loop. PDC were found to express high constitutive levels of IFN regulatory factor (IRF)7. IRF7 and STAT1, but not IRF3, were equally up-regulated by both CpG-A and CpG-B. CD40 ligand synergistically increased CpG-B-induced IFN-alpha independent of the IFNR but did not affect CpG-B-induced IFN-beta. In conclusion, our studies provide evidence for the existence of two distinct regulatory pathways of type I IFN synthesis in human PDC, one dependent on and one independent of the IFNR-mediated feedback loop. The alternate use of these pathways is based on the type of stimulus rather than the quantity of IFN-alphabeta available to trigger the IFNR. Constitutive expression of IRF7 and the ability to produce considerable amounts of IFN-alpha independent of the IFNR seem to represent characteristic features of PDC.

摘要

使用两种不同的CpG寡核苷酸(ODN)来研究人浆细胞样树突状细胞(pDC)中I型干扰素的调节:ODN 2216,一种CpG-A ODN,已知可在pDC中诱导大量干扰素-α;以及ODN 2006,一种CpG-B ODN,对刺激B细胞有效。与CpG-B ODN相比,CpG-A ODN显示出更高且持续时间更长的I型干扰素产生动力学。相反,CpG-B ODN在刺激IL-8产生以及增加共刺激分子和抗原呈递分子方面比CpG-A ODN更活跃,这表明CpG-A和CpG-B在pDC中触发了不同的调节途径。事实上,CpG-A ODN而非CpG-B ODN激活了I型干扰素受体(IFNR)介导的自分泌反馈回路。发现pDC表达高水平的干扰素调节因子(IRF)7。IRF7和信号转导和转录激活因子1(STAT1),而非IRF3,在CpG-A和CpG-B作用下均同等上调。CD40配体协同增加CpG-B诱导的干扰素-α,且不依赖于IFNR,但不影响CpG-B诱导的干扰素-β。总之,我们的研究为人类pDC中I型干扰素合成存在两种不同调节途径提供了证据,一种依赖于IFNR介导的反馈回路,另一种不依赖于此。这些途径的交替使用基于刺激的类型,而非可触发IFNR的干扰素-α/β的量。IRF7的组成性表达以及不依赖于IFNR产生大量干扰素-α的能力似乎代表了pDC的特征。

相似文献

1
Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells.用CpG-A和CpG-B寡核苷酸激活可揭示人类浆细胞样树突状细胞中I型干扰素合成的两种不同调节途径。
J Immunol. 2003 May 1;170(9):4465-74. doi: 10.4049/jimmunol.170.9.4465.
2
Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells.在浆细胞样树突状细胞中具有高诱导IFN-α/β作用的CpG寡核苷酸序列的鉴定。
Eur J Immunol. 2001 Jul;31(7):2154-63. doi: 10.1002/1521-4141(200107)31:7<2154::aid-immu2154>3.0.co;2-u.
3
Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation.浆细胞样树突状细胞衍生的干扰素-α在CpG寡脱氧核苷酸刺激后,通过人单核细胞诱导肿瘤坏死因子相关凋亡诱导配体/Apo-2L介导的抗肿瘤活性。
J Immunol. 2003 Jul 1;171(1):212-8. doi: 10.4049/jimmunol.171.1.212.
4
CpG-DNA-induced IFN-alpha production involves p38 MAPK-dependent STAT1 phosphorylation in human plasmacytoid dendritic cell precursors.CpG 脱氧核糖核酸诱导的干扰素-α 产生涉及人浆细胞样树突状细胞前体中 p38 丝裂原活化蛋白激酶依赖性 STAT1 磷酸化。
J Leukoc Biol. 2002 Nov;72(5):1011-9.
5
CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha.CpG-A诱导的单核细胞干扰素-γ诱导蛋白-10的产生受浆细胞样树突状细胞来源的干扰素-α调控。
J Immunol. 2003 Apr 15;170(8):4061-8. doi: 10.4049/jimmunol.170.8.4061.
6
Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12.Toll样受体表达揭示了CpG DNA是浆细胞样树突状细胞独特的微生物刺激物,它与CD40配体协同作用以诱导大量白细胞介素-12。
Eur J Immunol. 2001 Oct;31(10):3026-37. doi: 10.1002/1521-4141(2001010)31:10<3026::aid-immu3026>3.0.co;2-h.
7
Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.新型CpG寡核苷酸的合理设计,其可在浆细胞样树突状细胞中结合B细胞活化与高干扰素-α诱导。
Eur J Immunol. 2003 Jun;33(6):1633-41. doi: 10.1002/eji.200323813.
8
Rat plasmacytoid dendritic cells are an abundant subset of MHC class II+ CD4+CD11b-OX62- and type I IFN-producing cells that exhibit selective expression of Toll-like receptors 7 and 9 and strong responsiveness to CpG.大鼠浆细胞样树突状细胞是MHC II类+ CD4+CD11b-OX62-且产生I型干扰素的细胞的丰富亚群,其表现出Toll样受体7和9的选择性表达以及对CpG的强烈反应性。
J Immunol. 2004 Jun 15;172(12):7485-94. doi: 10.4049/jimmunol.172.12.7485.
9
CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells.CpG-A寡核苷酸诱导出一种单核细胞来源的树突状细胞样表型,该表型优先激活CD8 T细胞。
J Immunol. 2003 Apr 1;170(7):3468-77. doi: 10.4049/jimmunol.170.7.3468.
10
Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells.由CpG寡脱氧核苷酸激活的人浆细胞样树突状细胞可诱导CD4+CD25+调节性T细胞的产生。
J Immunol. 2004 Oct 1;173(7):4433-42. doi: 10.4049/jimmunol.173.7.4433.

引用本文的文献

1
Alternatively spliced isoforms of IRF7 differentially regulate interferon expression to tune response to viral infection.干扰素调节因子7(IRF7)的可变剪接异构体对干扰素表达进行差异性调控,以调节对病毒感染的反应。
Cell Rep. 2025 Aug 19;44(9):116166. doi: 10.1016/j.celrep.2025.116166.
2
Dynamic changes in immune cell subsets in blood and lymph node over the course of acute HIV infection.急性HIV感染过程中血液和淋巴结中免疫细胞亚群的动态变化。
J Virus Erad. 2025 May 26;11(2):100598. doi: 10.1016/j.jve.2025.100598. eCollection 2025 Jun.
3
Exploiting FcRn engagement of an albumin-CpG oligonucleotide covalent conjugate for potent TLR9 immune induction.
利用白蛋白-CpG寡核苷酸共价偶联物的FcRn结合作用实现有效的TLR9免疫诱导。
J Biol Chem. 2025 Apr 11;301(6):108508. doi: 10.1016/j.jbc.2025.108508.
4
CCL21 Induces Plasmacytoid Dendritic Cell Migration and Activation in a Mouse Model of Glioblastoma.CCL21在胶质母细胞瘤小鼠模型中诱导浆细胞样树突状细胞迁移和激活。
Cancers (Basel). 2024 Oct 12;16(20):3459. doi: 10.3390/cancers16203459.
5
Adenosine deaminase 2 regulates the activation of the toll-like receptor 9 in response to nucleic acids.腺苷脱氨酶 2 调节对核酸的 toll 样受体 9 的激活。
Front Med. 2024 Oct;18(5):814-830. doi: 10.1007/s11684-024-1067-5. Epub 2024 Jul 30.
6
Hold out the genome: a roadmap to solving the cis-regulatory code.伸出基因组:解决顺式调控代码的路线图。
Nature. 2024 Jan;625(7993):41-50. doi: 10.1038/s41586-023-06661-w. Epub 2023 Dec 13.
7
Control of A/D type CpG-ODN aggregates to a suitable size for induction of strong immunostimulant activity.将A/D型CpG寡脱氧核苷酸聚集体控制到合适大小以诱导强烈的免疫刺激活性。
Biochem Biophys Rep. 2023 Nov 3;36:101573. doi: 10.1016/j.bbrep.2023.101573. eCollection 2023 Dec.
8
TLR9 ligand sequestration by chemokine CXCL4 negatively affects central B cell tolerance.趋化因子 CXCL4 对 TLR9 配体的隔离作用会对中枢 B 细胞的耐受性产生负面影响。
J Exp Med. 2023 Dec 4;220(12). doi: 10.1084/jem.20230944. Epub 2023 Sep 29.
9
Challenges and opportunities in the development of combination immunotherapy with OX40 agonists.OX40 激动剂联合免疫疗法发展面临的挑战与机遇。
Expert Opin Biol Ther. 2023 Jul-Dec;23(9):901-912. doi: 10.1080/14712598.2023.2249396. Epub 2023 Aug 20.
10
Disruption of endosomal trafficking with EGA alters TLR9 cytokine response in human plasmacytoid dendritic cells.用 EGA 破坏内体运输会改变人浆细胞样树突状细胞中 TLR9 细胞因子的反应。
Front Immunol. 2023 Mar 20;14:1144127. doi: 10.3389/fimmu.2023.1144127. eCollection 2023.